Z6·尊龙凯时「中国」官方网站
Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Corporate Communications
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
中
繁
中
繁
中
Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Corporate Communications
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
Investor Relations
>
Investor Relations
>
Announcements and Circulars
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Corporate Communications
Announcements and Circulars
Search
Jan 07, 2021
Monthly Return
Read More
Dec 18, 2020
Business Update on Completion of Dawn (Hmm0302), Dorzagliatin’S Phase III Metformin Combination Trial Announcement of Potential Inside Information
Read More
Dec 03, 2020
Monthly Return
Read More
Nov 26, 2020
Voluntary Announcement – Update Regarding Recent Business Developments Hua Medicine Announces Additional Data in Beta-Cell Function
Read More
Nov 04, 2020
Monthly Return
Read More
Oct 07, 2020
Monthly Return
Read More
Sep 04, 2020
Monthly Return
Read More
Aug 19, 2020
Grant of Share Options
Read More
Aug 17, 2020
Business Update on Commercialization Agreement and Strategic Partnership for Investigational First-In-Class Novel Diabetes Treatment Dorzagliatin With Bayer in China Announcement of Potential Inside Information
Read More
Aug 17, 2020
Interim Results Announcement for the Six Months Ended June 30, 2020
Read More
Aug 05, 2020
Date of Board Meeting
Read More
Aug 05, 2020
Monthly Return
Read More
<<
<
6
7
8
9
10
11
12
13
14
15
16
>
>>
上一页
下一页
About Us
Company Overview
Company History
Leadership Team
Portfolio Advisory Board
Senior Scientific Advisory Board
Partner
Media center
Research & Development
Inovation
Pipeline
Dorzagliatin
mGluR5
Company Publications
Peer Reviewed Publications
Investor Relations
Corporate Governance
Financial Report
Announcements & Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock information
Media
Company News
Media Releases
Video
Careers
Culture
Join Us
Product
HuaTangNing(华堂宁®)
Subscribe Email
Focus Us
Copyright © 2024 Hua Medicine (Shanghai) Co., Ltd. 互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备99665955号-1
沪公网安备 31011502013809号
Privacy Statement
Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our
privacy statement
.
Accept
x
网站首页
Z6·尊龙凯时「中国」官方网站